Zoledronate Drug Holiday — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateMetabolic Bone DiseaseZoledronate Drug HolidaySCE Rheumatology

A 70-year-old woman with osteoporosis and two previous vertebral fragility fractures has, after specialist assessment, been selected for zoledronic acid 5 mg by annual intravenous infusion. Assuming it remains tolerated and no new contraindication develops, what total initial treatment duration should be planned under current UK guidance before a treatment interruption is considered?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — 6 years

The correct answer is A. Current NOGG guidance recommends planning 6 years of annual zoledronate when baseline factors indicate the need for extended treatment, including age at least 70 years, previous hip fracture, at least two vertebral fractures, or current glucocorticoid therapy. This patient meets both the age and vertebral-fracture criteria. Three years is the usual initial intravenous course and formal review point for patients without these extension factors; the NICE 3-year review does not mandate a drug holiday. Five years is the standard initial duration for oral bisphosphonates, while 10 years is the corresponding extended oral duration. One year is inadequate. The HORIZON extension also found fewer new morphometric vertebral fractures with 6 rather than 3 years of zoledronic acid.

Reference: Gregson CL et al. The 2024 UK clinical guideline for the prevention and treatment of osteoporosis — duration and monitoring of bisphosphonate treatment; intravenous bisphosphonate pathway. 2025. https://pubmed.ncbi.nlm.nih.gov/40921943/